Regeneron Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Regeneron Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Regeneron Pharmaceuticals: 280 sponsored US clinical trials, 61 recruiting.
Regeneron Pharmaceuticals sponsors 280 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 151 completed. 83 of these trials are in Phase 3-4 (later-stage) and 174 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 6 trials.
Top-decile sponsor footprint
Regeneron Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
151 of 190 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 6 of 6
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
NCT00964795
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
NCT01001923
A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
NCT00991172
Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers
NCT01026597
Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
NCT01001715
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers
NCT01015027
A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
NCT00944892
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
NCT00943072
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
NCT00871559
Study Utilizing Rilonacept in Gout Exacerbations
NCT00855920
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
NCT00856206
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
NCT00829829
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
NCT00856310
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
NCT01011959
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
NCT00789477
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
NCT00794417
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis
NCT01055899
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
NCT00610363
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
NCT00509795
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
NCT00527423
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
NCT00383370
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00320788
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
NCT00320814
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
NCT00288704
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
NCT01803321
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
NCT00320775
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00082823
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00083213
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
NCT00045266
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
NCT00036946
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 93 |
| Phase 2 | 81 |
| Phase 3 | 75 |
| Phase 4 | 8 |
What is open in the Regeneron Pharmaceuticals pipeline
61 recruiting of 280 indexed (22% open); 151 completed (54%).
Phase mix: 83 late (III/IV) vs 174 early (I/II) (early-phase heavy).
Top condition: Dermatitis, Atopic (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Regeneron Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 280 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Regeneron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Boston Scientific Corporation · 280 trials · 8% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AtriCure · 22% recruiting · 23 trials
- University of Colorado, Boulder · 22% recruiting · 69 trials
- University of Maryland, College Park · 22% recruiting · 46 trials
- Northwell Health · 22% recruiting · 370 trials
Related
What to do with this Regeneron Pharmaceuticals page
280 registered trials is a research-attention snapshot, not an endorsement of Regeneron Pharmaceuticals or any single study.
- 61 of Regeneron Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Regeneron Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Regeneron Pharmaceuticals pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.